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Background: X-linked intellectual disability is a common cause of inherited cognitive deficit affecting mostly males.
There are several genetic causes implicated in this condition, which has hampered the establishment of an accurate
diagnosis. We developed a multiplex-PCR assay for the mutational hotspot regions of the FMR1, AFF2 and ARX
genes.
Methods: The multiplex-PCR was validated in a cohort of 100 males selected to include known alleles for the FMR1
repetitive region: five full mutations (250–650 CGGs), ten premutations (70–165 CGGs) and eighty-five in the normal
range (19–42 CGGs). Sequencing or Southern blotting was used to confirm the results, depending on the allele
class. In this cohort, with the exception of one sample showing an AFF2 intermediate-sized allele, all other samples
were normal (8–34 CCGs). No ARX variant was found besides the c.429_452dup. The validated assay was applied to
5000 samples (64.4% males and 35.6% females).
Results: The normal-allelic range of both FMR1 and AFF2 genes as well as the nature of ARX variants identified was
similar in both genders. The rate of homozygosity observed in female samples, 27.5% for FMR1 and 17.8% for AFF2
alleles, is comparable to that published by others. Two FMR1 premutations were identified, in a male (58 CGGs) and
a female case [(CGG)47/(CGG)61], as well as several FMR1 or AFF2 intermediate-sized alleles. One AFF2 premutation
(68 CCGs) and two putative full expansions were picked up in male subjects, which seems relevant considering the
rarity of reported AFF2 mutations found in the absence of a family history.
Conclusions: We developed a robust multiplex-PCR that can be used to screen the mutational hotspot regions of
FMR1, AFF2 and ARX genes. Moreover, this strategy led to the identification of variants in all three genes,
representing not only an improvement in allele-sizing but also in achieving a differential diagnosis. Although the
distinction between females who are truly homozygous and those with a second pre- or full mutation sized allele,
as well as a definitive diagnosis, requires a specific downstream technique, the use of this multiplex-PCR for initial
screening is a cost-effective approach which widens the scope of detection.
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X-linked intellectual disability (XLID) is a group of genet-
ically heterogeneous disorders caused by mutations in X-
chromosome genes. Currently, it is believed that X-linked
recessive gene defects account for about 10–12% of overall
intellectual disability (ID) seen in males [1]. The lack of a
comprehensible relationship between clinical signs and
genotype in XLID, together with the large number of* Correspondence: jorgpaula@gmail.com
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reproduction in any medium, provided the orgenes implicated, are the major obstacles in their genetic
diagnosis and places ID as one of the most important un-
solved problems in healthcare. Nowadays, a huge amount
of information can be generated by assessing ID from both
the clinical and molecular point of view. However, the
challenge remains as to how all of this information can be
used to establish a simple, standard and effective strategy
applicable to molecular diagnosis and genetic counselling.
Among the genetic causes involved in XLID, mutations in
the genes FMR1 (fragile X mental retardation 1) and ARX
(aristaless related homeobox) emerge as important causes.
AFF2 (AF4/FMR2 family, member 2) testing is oftentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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larly in the absence of specific syndromic features [2-4].
The FMR1 gene contains polymorphic repetitive regions
susceptible to suffer dynamic mutations, a process that
may give rise to pathogenic expansions. The expansion to
over 200 CGG repeats in the FMR1 gene is associated
with fragile X syndrome [FXS, FRAXA; MIM#300624],
the most common form of familial severe XLID [5,6].
Below 200 repeats, alleles are classified as normal (5–44
CGGs), intermediate (45–54 CGGs) or premutated (55–
200 CGGs) (see also the Technical Standard and Guide-
line for Fragile X Testing, http://www.acmg.net/Pages/
ACMG_Activities/stds-2002/fx.htm, 2006 edition, last
accessed September 2012) [7].
Besides the X-chromosome fragile site A, fragile site
E (locus in Xq28) is also associated with intellectual
disability [FRAXE; MIM #309548]. This disorder is
mainly a non-syndromic form of X-linked intellectual
disability and is the result of silencing of the AFF2
gene, as a consequence of an upstream CCG expan-
sion [8]. In the normal population, the number of
CCG repeats varies between 6 and 35, while it is in-
creased to more than 200 hyper-methylated triplets in
FRAXE/AFF2 intellectually disabled patients. In con-
trast to FXS, reports of AFF2 full expansions are very
rare and the dynamics of this repeat is not as clearly
characterized as that of FMR1. Indeed, to what extent
the alleles with CCG repeats in the range between 36
and 199 may exhibit a pathogenic role remains elu-
sive, in part due to the rarity of the mutation and ex-
tended pedigrees [9].
In the ARX gene, the second exon represents a muta-
tional hotspot as it contains repetitive regions that codify
alanines. Since its identification, several mutations have
been identified, including insertions, deletions, duplica-
tions, missense, nonsense and splice mutations, leading
to a wide spectrum of phenotypes that include syndromic
as well as nonsyndromic forms of intellectual disability
[10]. These different mutations were reported in patients
with over 10 distinct clinical outcomes. Even though the
mutations described extend across the gene, the majority
occur in the largest coding exon of the ARX gene, exon 2,
where variations in polyalanine tracts, are among the most
frequent [11,12]. Indeed the c.429_452dup mutation, af-
fecting the second tract, is the most frequent ARX muta-
tion [13]. The absence of genotype/phenotype correlation
in the ARX gene explains our inability to establish the re-
spective guidelines for molecular screening particularly in
XLID patients that do not include brain malformations.
As the early recognition of syndromic physical traits is
difficult, it is widely accepted that boys with unexplained
ID/developmental delay, with or without any other clin-
ical findings, should be screened for FXS. The literature
supports the benefit of a screening method due to itsprevalence and the fact that molecular genetic testing
for FXS is highly sensitive and specific [14]. To the best
of our knowledge there is no reference to a three-gene
approach to the diagnosis of ID, specifically one that
covers two of the most frequently mutated XLID genes.
To address this issue we have developed a molecular test
based on a multiplex-PCR, focusing on mutational
hotspots of FMR1, AFF2 and ARX genes and validated
in a male cohort. Using this new assay we screened 5000
samples from male and female subjects referred for FXS
testing and have widened the identification of the gen-
etic causes of some XLID cases.
Methods
All genomic DNA (gDNA) samples had previously
been extracted by the salting out method, from per-
ipheral blood collected in ethylenediamine tetra
acetic acid (EDTA), dissolved in Tris-EDTA buffer
(pH = 7) and stored at 4°C [15]. No patients were
recruited specifically for this study; all samples be-
long to subjects previously referred by medical ge-
neticists for fragile X syndrome (FXS) molecular
testing [16]. Their phenotypic spectrum ranged from
severe intellectual disability to language delay or
learning disabilities with normal to borderline psy-
chomotor development. Approval for this study was
obtained from Ethics committee of the Instituto Nacional
de Saúde Dr. Ricardo Jorge (INSA, I.P.). The participants,
or their legally authorized representatives, had given in-
formed consent to take part in this research.
A validation cohort consisting of 100 male gDNAs was
chosen to include normal FMR1 alleles, ten FMR1
premutations and five full mutations. A sample with the
ARX mutation, c.429_452dup, was also used. This muta-
tion had previously been published and described as
c.428_451dup24 [17]. The test group comprised 5000
gDNAs of which 64.4% (n = 3220) were males and 35.6%
(n = 1780) females.
The method developed consisted in the combination
of three primer pairs that amplify target regions, as fol-
lows: FMR1, forward 6-FAM™ labelled 5′ CCA TCT TCT
CTT CAG CCC TGC 3′ and reverse 5′ TTC GGT TTC
ACT TCC GGT G 3′; AFF2, forward HEX labelled 5′
TGT GAG TGT GTA AGT GTG TGA TGC TGC C 3′
and reverse 5′ CCG CGC GCA CCC AGC GAC 3′ and
ARX, forward 5′ CAG CAG CCC TGG CTG GGA CTC
3′ and reverse HEX labelled 5′ CGG TAC GAC TTG
CTG CGG CTG 3′. While FMR1 and AFF2 amplicons
encompass the CGG and CCG polymorphic triplet re-
peats, respectively, the ARX exon 2 PCR (ARX ex2p), is
designed to amplify a portion of the second exon of ARX
gene, that includes two of the three stretches of repetitive
alanine coding triplets (poly AI and AII); a 380 bp
amplicon corresponding to the normal allele is produced
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amplicon. First, the optimization process was done using
each pair of primers in a separate amplification reaction
and tested for annealing temperatures ranging from 55°C
to 62°C. PCR components were then tested in a mul-
tiplexed reaction, one by one, in an empirically decided
order, namely primer amounts, extension time and con-
centration of several PCR co-adjuvants such as 7-deaza
dGTP, betaine and DMSO. The optimized multiplex-PCR
mixture prepared in a final volume of 25 μL contained a
final concentration of 1 M betaine, 0.12 mM each dATP,
dCTP and dTTP (Bioline, London, UK), 0.02 mM dGTP
(Bioline, London, UK), 0.4 mM 7-deaza dGTP, Li-Salt
(Roche, Indianapolis, USA), 4.8% DMSO (Sigma-Aldrich
Co, St. Louis, USA), 10 pmol FMR1 primers, 6 pmol
AFF2 primers, 5 pmol ARX primers and 1× Accutaq
buffer (Sigma-Aldrich Co, St. Louis, USA). This mixture
was supplemented with 1U AccuTaq polymerase
(Sigma-Aldrich Co, St.Louis, USA) and a total of 300 ng
of gDNA was added at the end. The amplification reac-
tion was performed in a 9800 Fast Thermal Cycler (Ap-
plied Biosystems, Foster City, CA, USA). After an initial
denaturation step for 10 minutes at 98°C, 42 cycles of
amplification were performed as follows: denaturation
at 98°C for 45 seconds, annealing at 58°C for 45 seconds
and extension at 68°C for 2 minutes and 30 seconds,
followed by an additional cycle of 10 minutes at 68°C
for the final extension. PCR products were diluted at
1:15 in a reaction solution containing 0.5 μL GeneScan™
500 ROX or MapMarker-1000-ROX, MapMarker®Size
Std (BioVentures, Inc., Murfreesboro, TN, USA) and
13.5 μL Hi-Di formamide (Applied Biosystems, Foster City,
CA, USA). Fragments were resolved on the 3130×l Genetic
Analyser and further analysed using the GeneMapper®
Software v4.0 (Applied Biosystems, Foster City, CA, USA).
Two types of methodologies were used to confirm the
results obtained in the validation cohort, according to
the allele class: sanger dideoxy sequencing for the
amplifiable fragments, using primer sets upstream and
downstream the FMR1 CGG, or AFF2 CCG repetitive
regions, or the ARX ex2p, and Southern blotting, for the
non-amplifiable fragments or alleles that fall into the
pathogenic range. Sequencing was performed using
BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) following the manu-
facturer’s indications with the primers described above
(without the fluorescent labelling) and standard amplifi-
cation conditions. Sequencing reactions were resolved
on a 3130×l Genetic Analyser. The resulting data were
further analysed using the SeqScape® Software v2.5
(Applied Biosystems, Foster City, CA, USA). Southern
blot genotyping was done using ~10 μg of gDNA
double-digested with the restriction enzymes EcoRI and
EagI for FMR1 gene or AflIII and NotI for AFF2 gene(New England Biolabs, Ipswich, MA, USA). Further, the
digested gDNA products were electrophoresed in parallel
with a 1:1 mixture of the standard size markers, DNA Mo-
lecular Weight Marker II and III digoxigenin-labeled
(Roche Applied Science, Indianapolis, IN, USA), blotted
and hybridized using the FMR1 or the AFF2 digoxigenin-
labeled specific probes, GLFXDIG1 or AJ31Dig1, as ap-
propriate (Gene Link™, Hawthorne, NY, USA).
Results and discussion
A screening strategy is described that allows the
characterization of FMR1 and AFF2 repetitive regions in
normal to premutation ranges together with the detec-
tion of size variants in the second exon of ARX gene.
The amplification of FMR1 CGG repetitive region has
been widely tested for several PCR conditions, either
changing polymerase or adding co-adjuvants [18-21].
Due to the high GC content in all three amplified frag-
ments and particularly in the repetitive amplified regions
(of FMR1 and AFF2 genes) leading to stutter band
formation, a directly comparative quantitative result was
not consistently obtained. Instead, we observed reduc-
tion in stutter band formation particularly in FMR1 al-
leles, in amplifications using this multiplex-PCR, when
compared to simplex reactions. Moreover, the simultan-
eous amplification of two similar fragments (FMR1 and
AFF2 polymorphic regions), in terms of GC content and
presence of triplet repeats, provides an internal amplifi-
cation control.
The validation cohort consisting of 100 male gDNAs
was sequenced across the FMR1 and AFF2 repetitive
regions and the ARX ex2p, used for allele number
standardization for each gene and for further validation of
the multiplex-PCR methodology. Table 1 compiles these
results. Examples of the optimized multiplex-PCR, se-
quencing and Southern blot results are shown in Figures 1
and 2. Overall, FMR1 CGG repeat sizes ranged from 19 to
over 120, where the 30 CGG repeat allele represented 37%
of the observed alleles. AFF2 CCG repeat sizes ranged
from 8 to 47 and alleles with 14 triplets represented 36%
of the pool [Figure 1-I(a) and II(b), Figure 2(f)]. Besides,
no other ARX sequence variant was observed [Figure 1-I
(b) and II(c)].
Samples with premutations and full mutations were on
purpose included in the validation process to test for
FMR1 primer specificity in the multiplex-PCR assay
[Figure 1-I(c)]. Expanded alleles were not the main pur-
pose of this assay and presented inconsistent amplifica-
tion results. Thus, the 110 CGG allele was settled as the
reliable upper-boundary for the sequencing validation
[Figure 1-II(a), Figure 2(b)]. Furthermore, whenever the
multiplex-PCR assay revealed either absence or an ex-
panded allele, the corresponding sample was subjected
to Southern blot analysis. An obvious gain when using
Table 1 Validation cohort results
n FMR1 CGG AFF2 CCG ARX (bp) n FMR1 CGG AFF2 CCG ARX (bp) n FMR1 (CGG) AFF2 (CCG) ARX (bp) Obtained/confirmed by
Southern bloting
1 19 13 380 3 30 11 380 1 33 22 380
1a 19 47 380 4 30 13 380 1 35 34 380
2 20 14 380 1b 30 14 404 2 36 14 380
1 20 15 380 14 30 14 380 1 37 23 380
1 21 14 380 1 30 15 380 1 41 23 380
1 21 15 380 1 30 16 380 1 42 23 380
1 21 23 380 4 30 17 380 1 65 14 380 ~70
3 23 14 380 2 30 18 380 1 71 14 380 ~70
1 23 16 380 1 30 19 380 1 75 23 380 ~80
2 23 17 380 2 30 20 380 1 80 22 380 ~80
2 23 19 380 1 30 22 380 1 85 14 380 ~80
1 23 20 380 1 30 24 380 1 100 15 380 ~100
1 24 14 380 2 30 27 380 1 110 14 380 ~100
1 27 14 380 1 31 14 380 1 120 15 380 ~120
1 28 20 380 2 31 17 380 1 - (150) 21 380 ~150
1 29 8 380 1 31 20 380 1 - 17 380 ~165
3 29 14 380 1 31 21 380 1 - 16 380 ~250
1 29 15 380 1 31 30 380 1c 51 22 380 ~350
1 29 16 380 2 32 14 380 1 - 17 380 ~350
1 29 9 380 1 32 15 380 1 - 14 380 ~400
4 29 17 380 1 32 19 380 1 - 13 380 ~650
Number of triplets obtained for FMR1 and AFF2 genes, and ARX ex2p fragment size, in 100 male samples. The order is according to FMR1 allele sizes. Number of
triplets obtained for FMR1 and AFF2 genes, and ARX ex2p fragment size, in 100 male samples, ordered according to FMR1 allele sizes. [n] Number of samples per
allele profile; aAFF2 intermediate size allele; bcontrol for the ARX c.429_452dup; cFXS sample with mosaicism for an intermediate-size allele and a full mutation;
Premutations clearly amplified by the multiplex-PCR and additionally confirmed by sequencing are bold highlighted; [−] not (reproducibly) amplified.
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is the accuracy with which the allele-sizes are quantified,
with emphasis in the clinically significant borderline
alleles (Table 1).
In a sample belonging to a FXS patient (banked as a
full mutation carrier) the multiplex-PCR assay revealed a
fragment corresponding to a 51 CGG allele [Figure 1-I
(d)]. Having excluded a sample identification error, an-
other possible explanation for that finding, is that the
blot (performed more than 16 years ago with an FMR1
specific 32P-labelled probe) may not have had sufficient
sensitivity to pick up low levels of mosaicism or the
expected intermediate band could have become imper-
ceptible to the naked eye. With the aim of validating this
result, an additional Southern blot analysis was performed
in which, besides the full mutation, a faint intermediate-
sized band, was observed, consolidating the multiplex-
PCR result [Figure 2(a)]. This example illustrates that this
assay or any other PCR-based methodology used as a
screening test per se, is unable to exclude size-mosaicism.
As such, it is recommended to exclude the presence of
size-mosaics resorting to a different methodology(e.g. Southern blot), particularly in the presence of strong
clinical features or FXS family history.
The validated multiplex-PCR assay was applied to
5000 samples (test group), previously screened for FMR1
expansions by Southern blot methods only. 64.4% of the
analysed alleles were from male samples (n = 3220)
(Figure 3). In this subset, the FMR1 alleles ranged from
8 to 58 repeats, where the 54 CGG allele is the largest
within the normal range, while AFF2 alleles ranged from
6 to 68 CCGs, being the 44 repeat allele the largest
among the normal. Alleles containing 29 CGG repeats
and 14 CCG repeats were seen to be the most frequent,
representing 35.0% and 33.1% of the FMR1 and AFF2 al-
leles respectively. FMR1 male intermediate-sized alleles
(41 to 54 CGGs) revealed a frequency of 3.2%, while for
AFF2 gene only 0.71% fall into this category (31 to 44
CCGs). Although a direct comparison is difficult, these
frequencies are comparable to those described in a simi-
lar survey focusing on the parameters used for the sam-
ple selection (using an inclusive rather than an exclusive
selection) [9]. In a more recent study of a male subject
control population, higher frequencies were obtained:
(a) FMR1 – 110 CGG
(b) AFF2 – 47 CCG
(c) ARX – c.429_452dup
poly AI
poly AII
II
31 CGG
15 CCG
380 bp
19 CGG
47 CCG
(b)
380 bp 120 CGG
(a)
I
380 bp
51 CGG
22 CCG
(c)
(d)
14 CCG
404 bp
Figure 1 (See legend on next page.)
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Figure 1 Examples of validation cohort results. I-Multiplex-PCR assay for the analysis of the mutational hotspot of FMR1 CGG alleles (blue
label), AFF2 CCG alleles (green label) and ARX ex2p (380 bp green fragment). Profile: (a) AFF2 intermediate allele (47 CCGs); (b) c.429_452dup of
ARX gene; (c) FMR1 premutation (120 CGGs); (d) FXS male mosaic with an FMR1 intermediate allele (51 CGGs) and a full mutation. II-Sequencing
results: (a) CGG repetitive region of FMR1 gene (sense strand) showing the reproducibly sequenced premutated allele with 110 triplets; (b) AFF2
intermediate allele (47 CCGs) (reverse strand); (c) Partial nucleotide sequence of the ARX gene exon 2 (sense strand), showing the prevalent ARX
mutation c.429_452dup. The box indicates the most upstream twenty-four base pair sequence that is duplicated. The two stretches of repetitive
triplets coding for alanine (poly AI and AII) are underlined.
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sized alleles (Supplemental Table one in [22]). However,
in that report a comparatively small number of samples
were analysed (n = 124).
Regarding the AFF2 gene, this multiplex-PCR assay
revealed two presumed full mutations (2 in 3220), in
which there was an unsuccessful amplification of the
AFF2 allele and a case with an allele in the premutation
range with 68 CCG repeats (1 in 3220) [Figure 2(g),
Figure 3 and Figure 4(a)]. A definitive diagnosis of these
cases requires a specific downstream technique; hence
analyses by Southern blot using an AFF2 specific probe,
as well as familial studies are being performed. The
putative association of AFF2 premutated alleles with the
development of Parkinson disease in adulthood, the risk
of expansion to pathogenic mutations in future genera-
tions as well as non-syndromic/non-pathognomonicFigure 2 Examples of Southern blot results. Genotyping using FMR1 pr
fragments, a ~2.8 kb (active X) and a ~5.2 kb (inactive X), while in normal m
CGG allele and a full mutation; (b) Premutated FMR1 male (110 CGGs); (c) K
the inactive X-chromosome; (d) Normal FMR1 male (19 CGGs); (e) Premuta
AflIII /NotI double digestion, normal females present two fragments, a ~2.2
only a ~2.2 kb fragment: (f) Intermediate AFF2 male (47 CCGs); (g) Premutaclinical signs in AFF2 mutation carriers, justifies muta-
tion screening for this gene and are obvious benefits of
AFF2 gene analysis included in this multiplex-PCR [22].
Co-amplification of AFF2 and FMR1 has also proven
useful in detecting X-chromosome aneuploidy. In in-
formative samples when the number of amplified
fragments is inconsistent with the number of expected
X-chromosomes (according to patient gender) or there
appears to be a discrepancy between the number of al-
leles for the different genes, further investigation must
be done. In fact, we found nineteen of such cases in which
the karyotype subsequently confirmed a Klinefelter syn-
drome, representing 0.59% of the analysed male samples,
a frequency similar to others previously reported [Figure 2
(c), Figure 4(b) and (c)] [9]. Surprisingly, in a 47, XXY case,
a fully-methylated FMR1 gene mutation was recently
identified (data not shown).obe: After EcoRI /EagI double digestion, normal females exhibit two
ales only a ~2.8 kb fragment is seen: (a) FXS male mosaic for a 51
linefelter with two FMR1 normal sized-alleles, showing the active and
ted FMR1 male (58 CGGs). Genotyping using AFF2 probe: Following
kb (active X) and a ~4.8 kb (inactive X), whereas normal males exhibit
ted AFF2 male (68 CCGs); (h) Homoallelic female [(CCG)14/(CCG)14].
na 6 8 10 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 40 41 44 68 %
8 1
10 1
12 1
14 1
15 1 2
16 1 1 1
17 2 1 1
18 1 2 2 2 1 1
19 1 4 3 4 14 85 30 16
 20 f 13 8 4 3 9 3 2 3 1 3 3 1 1 1
20 1 2 29 11 2 1 1 7 4 4 1
 3 b 2 2 1 1 1
21 1 2 4 25 9 3 6 3 5 1 3 4 1 1 1 1
22 2 1 2 4 47 16 9 20 14 8 4 7 2 2 6 1 1 1 1 1
23 1 4 27 4 3 8 2
 9 b 2 3 1
24 1 13 4 2 7 1 4
25 1 2 6 1 1 5 1 1 1 1 1
26 1 3 7 5 2 1 2 1 1 1
27 8 1 1 3 1 1 2 1 1
28 5 8 15 80 30 32 61 22
 19 g 14 9 10 10 6 3 3 1 1
29 1 6 12 30
 78 b 351 125 81 131  65 e 58 25 24 28 36 23 17 3 12 6 6 3 1 2 1 2 35,0
30 2 4 7 5 34
 180 d,g 59  26 g  62 a 25 23 9 8 11 10 5 3 5 3 1 1
31 2 2 8 78 22 13 15 4 12
 4 c 6 12 7 3 2 2 2
32 1 2 2 4 27 10 7 10 4 3 2 3 1 2 1 1 2 2
33
 1 a 2 11 2 1 3 2 1 2 1 1 1 1
34 3 6 2 2 1
35 8 1 1 2 5 1 2 2
36 1 1 6 4 3 2 1 2 2 2 1 1
37 1 3 11 1 1 1 3 1 1
38 1 8 7 5 4 2 1 1 1 1
39 3 1 6 8 4 2 1 1 2 1 1
40 1 3 3 2 1 1 1 1 1 1 1
41 1 3 5 1 1 1
 4 g 1
42 4 1 3 1 2 1
43 7 2 1 2 1 1
44 1 1 4 2 4 1 1 1 1
45 1 1 6 1 3 1 3 2 1 1
46 1 2 1 1
47 3 2
48 2 1 1
49 1 1
50 1 1
51 1 1
52 3 1
54 1
58 1
% 33,1
AFF2
FM
R1
deletion insertion/duplication insertion/duplication/deletion
Figure 3 Test group results. Number of male samples per allele profile of both FMR1 and AFF2 loci. Intermediate alleles are grey shaded. In dark
grey the premutations identified in both FMR1 and AFF2 are shown. Percentage of the most frequently identified allele for both genes is
indicated. Cases with different ARX variants are surrounded by boxes. [na] – absence of amplification for AFF2 gene. ARX variant type: a9 bp
deletion (two samples); b15 bp deletion (three samples); c24 bp deletion; d33 bp deletion; e3 bp insertion/duplication; f12 bp insertion/
duplication; g24 bp insertion/duplication (four subjects). Klinefelter cases are not represented as the allelic phase was unknown.
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served in the ARX gene by fragment analysis, including
seven deletions (ranging from 9 to 33 bp) and six inser-
tions or duplications (represented by an increase in size
of 3 to 24 bp) (Figure 3). Subsequent sequencing revealed
four cases with the known ARX mutation (c.429_452dup)
as well as several other variants that change the alaninecontent of the ARX protein. Segregation studies and geno-
type/phenotype correlations are being completed. ARX
pathogenic variants characterized to date are the cause of
at least ten clinically distinct conditions, where intellectual
disability is the cardinal feature [10]. The vast majority of
mutations occurring outside known ARX domains or in
domains other than the polyalanine (poly A) tracks are
19 CGG 
68 CCG 
380 bp
(a) 
380 bp
58 CGG 
14 CCG (e) 
380 bp
29 CGG 31 CGG 
17 CCG 
22 CCG 
(b) 
30 CGG 
29 CGG 
15 CCG 
380 bp365 bp
(d) 
17 CCG 
380 bp
19 CGG 
22 CCG 
(c) 
26 CCG 
380 bp61 CGG 
47 CGG 23 CCG (f) 
24 CCG 
Figure 4 Examples of test group results. Multiplex-PCR assay focusing the analysis of the mutational hotspot of FMR1 CGG alleles (blue label),
AFF2 CCG alleles (green label) and of the ARX ex2p (380 bp green fragment). Profiles: (a) AFF2 premutation male (68 CCGs); (b) and (c) male
samples where the karyotype revealed the presence of an extra X-chromosome (47, XXY). Additionally in (c) an FMR1 full mutation was
subsequently identified by Southern blotting. Profiles: (d) Heterozygous ARX exon 2 deletion female; (e) and (f): FMR1 premutation alleles, male
(58 CGGs) and female [(CGG)47/(CGG)61]. Both FMR1 (d) and AFF2 (f) alleles differing in size by a single triplet can be easily distinguished.
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orders (e.g. X-linked lissencephaly with ambiguous geni-
talia). However, patients showing one or more of these
particular features were not incorporated in the present
survey. On the contrary, mutations that result in a poly A
expansion account for 59% of ARX mutations encoun-
tered in familial or isolated ARX-related cases [10].
Considering that our multiplex-PCR method is able to
pinpoint deletions as well as expansions in the first two
poly A stretches and that the latter are known to be the
most frequent cause of ARX-related disorders, we can as-
sume that the vast majority of the ARX-related variants of
the test group male samples had been assessed.
In the females group, that represents 35.6% (n = 1780)
of the analysed subjects, the allelic range of both FMR1
and AFF2 genes was similar to that obtained in male
samples including several FMR1 or AFF2 intermediate-
sized alleles. Southern blot for the analysis of FMR1 orAFF2 genes was carried out to discard a premutation or
a full mutation in the case of an apparently homozygous
women. Simultaneous FMR1 and AFF2 homoallelic sam-
ples were found in 5.8% of the female subjects (n = 103)
whereas private homoallelism for FMR1 or AFF2 genes,
occurred respectively in 27.5% (n = 490) and 17.8%
(n = 317) of the samples [Figure 2(h)]. Considering the
homoallelic females, the pairs [(CGG)29/(CGG)29] and
[(CCG)14/(CCG)14] were observed in 73.4% and 71.8% of
samples, respectively. As such, the results obtained in
these two subsets of samples were used for an overall
representation of the female samples [Figure 5(a) and (b)
respectively]. In the females group, the number of ARX
variants, was, as expected, significantly less than that ob-
served in males: four size-variants of which three are de-
letions, ranging from 6 to 15 bp, and one is an insertion/
duplication of 24 bp. The sample with a 15 bp deletion
in ARX exon 2 has the following allelic profile [(CGG)29/
(a) AFF2
6 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 34 36 38
6 1
11 2 1 1 1 1 1 1 1
12 3 1 1
13 6 18
 3 b 3 2 4 1 1 1 2 1 1 1 1
14 43 16 12 16 7 7 3 2 5 2 2 3 2 2 1 1 3 1
15 14 5 4 1 2 1 2 1 1 3 1
16 4 10 2 1 1 1
17 5 2 1 2 4 2 1 2 1 1
18 1 1 1
19 1 1 2
20 1 2 1
21 1 1 1
22 1
(b)
FMR1
19 22 24 27 28 29 30 31 32 33 34 35 36 38 40 41 42 45 47 48 50 52
19 3 1 1 2 9 3 2 1 1
20 1 5 1 1 1
21
22 1 1 2 1 6 2 1 1 1 1 1 1
23 1 1
24
25 2
26 1 2
27 1 2 1
28 1 6 15
 4 c 2 1  2 a 1 1 1
29 43 7 7 1 1 1 1 2 1
30 4 1 1 1 1 1
31 2 1 1 1
32 1
34 1
 allele 2
al
le
le
 1
 allele 2
al
le
le
 1
AFF2
(CCG)14/(CCG)14
FMR1
(CGG)29/(CGG)29
deletion insertion/duplication
Figure 5 Test group results. Number of female homoallelic samples per allele profile of (a) FMR1 [(CGG)29/(CGG)29] and (b) AFF2 [(CCG)14/
(CCG)14]. Intermediate alleles are grey shaded. Cases with different ARX variants are surrounded by boxes. ARX variant type:
a6 bp deletion;
b15 bp deletion; c24 bp insertion/duplication.
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ARX variants occurred in FMR1 or AFF2 homoallelic
samples [Figure 4(d) and Figure 5(a) and (b)]. The
pathogenic status of these variants, all occurring in a
heterozygous state, remains to be determined.
Our test group includes subjects referred for FXS con-
firmation/exclusion, in the early 90s, classified as having
a normal FMR1 profile (by Southern blot). However, two
FMR1 premutations were now identified in a male (58
CGGs) and a female case [(CGG)47/(CGG)61] [Figure 2
(e), Figure 3 and Figure 4(e) and (f)]. The blot was re-
peated using non-isotopic labelling, where these fragmentswere evident. We thus attributed the initial discrep-
ancy to the relatively small size of the premutations,
difficult to resolve under the older electrophoretic
and labelling conditions. Despite Southern blotting
and hybridization being the gold standard for mo-
lecular diagnosis of FXS and detection of mosaics,
our results clearly illustrate the contribution of a
PCR screening, particularly since it facilitates the de-
tection and size-quantification of intermediate and
premutated alleles.
The transition from an intermediate-sized allele to a full
mutation in a single transmission was never observed,
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meiosis, which adds instability to those alleles [23]. The
identification of these, probably unstable, alleles is of ex-
treme importance since appropriate genetic counselling can
be offered. Therefore, the benefits of the screening test are
not limited to the subject tested but also are extended
to other family members. Another added value concerns
the FMR1 premutation carriers that, until recently, were
not considered at risk for any clinical disorder, however
nowadays the role of these alleles in terms of female
reproduction, namely in fragile X-associated primary ovar-
ian insufficiency (FXPOI) cases and, in older individuals, in
fragile X–associated tremor/ataxia syndrome (FXTAS) has
been highlighted [24,25].
Based on our experience in FXS testing, one can esti-
mate that around 3.5% of male and ~1% of female sam-
ples will not amplify the FMR1 CGG repetitive region
due to a mutation. Although unsuccessful amplification
can be attributed to several factors (e.g. SNP in primer
ligation site, deletion or technical pitfall) we do not have
any such examples in our records as all these cases had
a confirmed full mutation or large-premutation or both,
confirmed by Southern blotting. Absence of amplifica-
tion can occur due to the same factors described above
in AFF2 or ARX testing. For these two genes no esti-
mates can be made as a larger cohort, specifically re-
ferred due to intellectual disability, has to be analysed.
Conclusion
Overall, this multiplex-PCR assay can be beneficially used
as a screening assay for FMR1 gene premutations under
110 CGGs, AFF2 gene premutations under 70 CCGs and
ARX exon 2 size-variants. This methodology allows the
screening of a considerable number of male and female
samples with the same sensitivity/specificity as the simplex
methodology and an enhanced accuracy when compared to
Southern blot. Based on our results, 0.031% of male size-
mosaics might be unnoticed. In addition, this methodology
will not detect very rare cases of point mutations or dupli-
cations/deletions outside the hotspots of the three genes. In
females, this screening shall unravel ~70% of FMR1 and
~80% of AFF2 gene analysis. Final mandatory diagnosis of
homoallelic cases, size and methylation mosaics, X-
chromosome aneuploidies, or FMR1, AFF2 and ARX gene
mutation are not aims of this methodology and must,
thus, be achieved with other appropriate diagnostic tech-
niques (e.g. Southern blotting, sequencing, methylation-
specific PCR/MLPA or karyotyping). To overcome the
putative overlap between the ARX fragment and an AFF2
allele, an improvement would be the use of NED™ label-
ling instead of HEX, in either the ARX or the AFF2
primer. Besides being rapid and cost-effective, this
multiplex-PCR assay proved to be suitable as a high
throughput screening strategy covering the previouslymentioned XLID related conditions, representing a step
forward in guiding the molecular approach and ultimately
patient management, particularly in cases with difficult
clinical ascertainment. This is definitely the case of ARX
gene mutations that include different mutational phenom-
ena but also a clear hotspot that accounts for at least 60%
of ARX mutations [26,27]. In reports of patients with no
obvious phenotype this number is usually increased. In
fact, we found seventeen ARX variants in our cohort of pa-
tients that showed no obvious phenotypic feature. In con-
clusion, laboratories performing molecular genetic studies
of idiopathic intellectual disability would benefit from the
implementation of this methodology, which enables a wid-
ened scope of detection of the mutational hotspot regions
of FMR1, AFF2 and ARX genes in a single initial assay.
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